Dihydrogenated alkaloids of ergot in geriatric patients: symptomatic treatment of cerebrovascular insufficiency
Kaye, C.
Boletin de la Asociacion Medica de Puerto Rico 64(11): 301-303
1972
ISSN/ISBN: 0004-4849 PMID: 4205800 Document Number: 701029
Document emailed within 1 workday
Related Documents
Vaupel, P.; Hutten, H. 1980: Acute changes in intracerebral vascular resistance after application of dihydrogenated ergot alkaloids Arzneimittel-Forschung 30(4): 598-602Loew, D.M.; Depoortere, H.; Buerki, H.R. 1976: Effects of dihydrogenated ergot alkaloids on the sleep-wakefulness cycle and on brain biogenic amines in the rat Arzneimittel-Forschung 26(6): 1080-1083
Robbers, J.E.; Jones, L.G.; Krupinski, V.M. 1974: Ergot physiology. the production of ergot alkaloids in saprophytic culture by a homokaryotic strain of ergot Lloydia 37(1): 108-111
Dauverchain, J. 1979: The role of nicergoline in the symptomatic treatment of arterial hypertension and chronic cerebrovascular insufficiency. a study on 359 observations Arzneimittel-Forschung 29(8a): 1308-1310
Cucinotta, D.; Palummeri, E.; Carapezzi, C.; Cocchi, C. 1979: Therapy of chronic cerebrovascular arteriosclerotic insufficiency in a geriatric patient Giornale di Clinica Medica 60(3): 225-233
Venn, R.D. 1976: Electroencephalogram and ergot alkaloids Postgraduate Medical Journal 52suppl. 1: 55-56
Walter, U. 1979: Risks of ergot alkaloids in obstetrics Medizinische Monatsschrift für Pharmazeuten 2(3): 76-80
Sterzl, J.; Rehácek, Z.; Cudlín, J. 1987: Regulation of the immune response by ergot alkaloids Czechoslovak Medicine 10(2): 90-98
Bernardi, L. 1979: From ergot alkaloids to nicergoline/Chemical points of view Arzneimittel-Forschung 29(8a): 1204-1206
Schran, H.F.; Schwarz, H.J.; Talbot, K.C.; Loeffler, L.J. 1979: Specific radioimmunoassay of ergot peptide alkaloids in plasma Clinical Chemistry 25(11): 1928-1933
Gorini, A.; Arnaboldi, R.; Vercesi, L.; Dossena, M. 1988: Influence of some ergot alkaloids on the cerebral reduced glutathione Il Farmaco; Edizione Scientifica 43(11): 887-890
Mercier, C. 1982: Peptide alkaloids of spurred rye and their semisynthetic derivatives. III. Ergot in therapeutics Journal de Pharmacie de Belgique 37(4): 289-298
Floss, H.G.; Basmadjian, G.P.; Tcheng, M.; Gröger, D.; Erge, D. 1971: Biosynthesis of peptide-type ergot alkaloids. Ergocornine and ergocryptine Lloydia 34(4): 446-448
Eich, E.; Pertz, H. 1994: Ergot alkaloids as lead structures for differential receptor systems Die Pharmazie 49(12): 867-877
Schmitt, H.; Fenard, S. 1970: Effects of ergot alkaloids on the vasomotor centers and their inhibition by clonidine Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales 164(5): 1006-1009
Gröger, D.; Syring, U.; Johne, S. 1975: Syntheses of radioactive cyclols as potential precursors of the peptide moiety of ergot alkaloids Die Pharmazie 30(7): 440-443
Kozlovskiĭ, A.G.; Zhelifonova, V.P.; Antipova, T.V.; Zelenkova, N.F. 2011: Physiological and biochemical characteristics of fungi of the genus Penicillium as producers of ergot alkaloids and quinocitrinins Prikladnaia Biokhimiia i Mikrobiologiia 47(4): 469-473
Sarsúnová, M.; Semonský, M.; Cerný, A. 1970: Ergot alkaloids. XXXVI. Separation of diastereomeric (+)-1-hydroxy-2-butylamides of D- and L-lysergic and D- and L-isolysergic acids by thin-layer chromatography Journal of Chromatography 50(3): 442-446
Pezzuoli, G. 1980: Surgery and results in the treatment of cerebrovascular insufficiency Minerva Medica 71(29): 2092-2093
Ionescu, M.; Hemett, O.M.; Descombes, E.; Blondel, N.; Hayoz, D. 2014: Geriatric patients with chronic kidney insufficiency: which antalgia? Revue Medicale Suisse 10(425): 804; 806-810